Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands.
J Nucl Med. 2013 Aug;54(8):1294-301. doi: 10.2967/jnumed.112.117614. Epub 2013 Jun 7.
In hepatic (90)Y radioembolization, pretreatment (99m)Tc-macroaggregated albumin ((99m)Tc-MAA) nuclear imaging is used for lung shunt analysis, evaluation of extrahepatic deposition, and sometimes for treatment planning, using a partition model. A high level of agreement between pretreatment (99m)Tc-MAA distribution and final (90)Y-microsphere distribution is assumed. The aim of this study was to investigate the value of pretreatment (99m)Tc-MAA SPECT to predict intrahepatic posttreatment (90)Y-microsphere distribution.
Volumes of interest (VOIs) were delineated on pretreatment contrast-enhanced CT or MR images according to Couinaud liver segmentation. All VOIs were registered to the (99m)Tc-MAA SPECT and (90)Y SPECT images. The (99m)Tc-MAA SPECT and (90)Y SPECT activity counts were normalized to the total administered activity of (90)Y. For each VOI, this practice resulted in a predictive amount of (90)Y (MBq/cm(3)) based on (99m)Tc-MAA SPECT in comparison with an actual amount of (90)Y based on (90)Y SPECT. Bland-Altman analysis was used to investigate the agreement of the activity distribution between (99m)Tc-MAA SPECT and (90)Y SPECT.
A total of 39 procedures (225 VOIs) in 31 patients were included for analysis. The overall mean difference between pretreatment and posttreatment distribution of activity concentration for all segments was -0.022 MBq/cm(3) with 95% limits of agreement of -0.581 to 0.537 MBq/cm(3) (-28.9 to 26.7 Gy absorbed dose). A difference of >10%, >20%, and >30% of the mean activity per milliliter was found in, respectively, 153 (68%), 97 (43%), and 72 (32%) of the 225 segments. In every (99m)Tc-MAA procedure, at least 1 segment showed an under- or overestimation of >10%. The position of the catheter tip during administrations, as well as the tumor load of the liver segments, significantly influenced the disagreement.
In current clinical practice, (99m)Tc-MAA distribution does not accurately predict final (90)Y activity distribution. Awareness of the importance of catheter positioning and adherence to specific recommendations may lead to optimization of individualized treatment planning based on pretreatment imaging.
研究预处理(99m)Tc-MAA SPECT 预测肝内(90)Y 微球治疗后分布的价值。
根据 Couinaud 肝段在对比增强 CT 或 MR 图像上划定感兴趣区(VOI)。所有 VOI 均与(99m)Tc-MAA SPECT 和(90)Y SPECT 图像配准。(99m)Tc-MAA SPECT 和(90)Y SPECT 的放射性计数与(90)Y 的总给药活度归一化。对于每个 VOI,基于(99m)Tc-MAA SPECT 计算出(90)Y 的预测量(MBq/cm(3)),并与(90)Y SPECT 实际(90)Y 量进行比较。Bland-Altman 分析用于研究(99m)Tc-MAA SPECT 和(90)Y SPECT 之间的活性分布一致性。
共纳入 31 例 39 例(225 个 VOI)进行分析。所有节段的活性浓度预处理与治疗后分布的总体平均差异为-0.022 MBq/cm(3),95%一致性区间为-0.581 至 0.537 MBq/cm(3)(-28.9 至 26.7 Gy 吸收剂量)。在 225 个 VOI 中,分别有 153 个(68%)、97 个(43%)和 72 个(32%)的活性平均值差异超过 10%、20%和 30%。在每个(99m)Tc-MAA 过程中,至少有 1 个节段的测量值存在低估或高估超过 10%。给药过程中导管尖端的位置以及肝段的肿瘤负荷显著影响不一致性。
在当前的临床实践中,(99m)Tc-MAA 分布不能准确预测最终(90)Y 活性分布。意识到导管定位的重要性并遵守特定的建议可能会导致基于预处理成像的个体化治疗计划的优化。